Top Regulatory News Stories – Week Ending May 11, 2018

The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.  http://www.pharmacytimes.com/news/fda-approves-drug-combination-for-treating-brafpositive-anaplastic-thyroid-cancer The FDA has promised Roche/Genentech a priority review for Tecentriq plus Avastin and chemo for lung cancer, with[…]